Bliss GVS Pharma Ltd — Profit & Loss Statement

₹215.59

-3.69%

Bliss GVS Pharma Ltd Profit & Loss Statement (Annual)

Metric	2025	2024	2023	2022
EBITDA	161.23 Cr	148.81 Cr	127.99 Cr	74.43 Cr
EBIT	131.82 Cr	122.43 Cr	109.32 Cr	57.09 Cr
Net Interest Income	8.60 Cr	5.37 Cr	3.76 Cr	4.84 Cr
Interest Expense	6.18 Cr	5.56 Cr	3.24 Cr	2.93 Cr
Interest Income	15.15 Cr	11.79 Cr	7.50 Cr	8.82 Cr
Normalized Income	84.07 Cr	102.48 Cr	72.10 Cr	78.40 Cr
Net Income From Continuing And Discontinued Operation	84.30 Cr	75.45 Cr	70.86 Cr	15.04 Cr
Total Expenses	704.04 Cr	631.15 Cr	646.70 Cr	619.78 Cr
Rent Expense Supplemental	1.19 Cr	1.65 Cr	1.90 Cr	1.56 Cr
Diluted Average Shares	10.60 Cr	10.61 Cr	10.55 Cr	10.52 Cr
Basic Average Shares	10.51 Cr	10.43 Cr	10.38 Cr	10.33 Cr
Diluted EPS	7.95	7.11	6.72	1.43
Basic EPS	8.02	7.23	6.83	1.46
Diluted NI Availto Com Stockholders	84.30 Cr	75.45 Cr	70.86 Cr	15.04 Cr
Net Income Common Stockholders	84.30 Cr	75.45 Cr	70.86 Cr	15.04 Cr
Otherunder Preferred Stock Dividend	0.00	0.00	0.00	0.00
Net Income	84.30 Cr	75.45 Cr	70.86 Cr	15.04 Cr
Minority Interests	-5.96 Cr	-6.12 Cr	-5.88 Cr	-8.09 Cr
Net Income Including Noncontrolling Interests	90.26 Cr	81.58 Cr	76.73 Cr	23.13 Cr
Net Income Continuous Operations	90.26 Cr	81.58 Cr	76.73 Cr	23.13 Cr
Tax Provision	35.38 Cr	35.29 Cr	29.34 Cr	31.04 Cr
Pretax Income	125.64 Cr	116.87 Cr	106.07 Cr	54.17 Cr
Other Non Operating Income Expenses	4.52 Cr	4.81 Cr	2.15 Cr	2.40 Cr
Special Income Charges	-0.16 Cr	-39.42 Cr	-1.72 Cr	-90.66 Cr
Other Special Charges	0.16 Cr	-0.29 Cr	-0.37 Cr	73.53 Cr
Write Off	0.00	39.71 Cr	2.08 Cr	17.13 Cr
Net Non Operating Interest Income Expense	8.60 Cr	5.37 Cr	3.76 Cr	4.84 Cr
Total Other Finance Cost	0.37 Cr	0.86 Cr	0.50 Cr	1.05 Cr
Interest Expense Non Operating	6.18 Cr	5.56 Cr	3.24 Cr	2.93 Cr
Interest Income Non Operating	15.15 Cr	11.79 Cr	7.50 Cr	8.82 Cr
Operating Income	97.76 Cr	134.76 Cr	100.73 Cr	118.14 Cr
Operating Expense	290.35 Cr	249.03 Cr	245.37 Cr	228.80 Cr
Other Operating Expenses	72.13 Cr	52.83 Cr	71.44 Cr	67.44 Cr
Depreciation And Amortization In Income Statement	29.42 Cr	26.38 Cr	18.67 Cr	17.33 Cr
Depreciation Income Statement	29.42 Cr	26.38 Cr	18.67 Cr	17.33 Cr
Research And Development	29.30 Cr	33.73 Cr	21.79 Cr	22.00 Cr
Selling General And Administration	54.07 Cr	43.09 Cr	49.44 Cr	53.78 Cr
Selling And Marketing Expense	44.28 Cr	34.68 Cr	42.17 Cr	45.18 Cr
General And Administrative Expense	9.79 Cr	8.41 Cr	7.28 Cr	8.60 Cr
Rent And Landing Fees	1.19 Cr	1.65 Cr	1.90 Cr	1.56 Cr
Gross Profit	388.11 Cr	383.79 Cr	346.10 Cr	346.95 Cr
Cost Of Revenue	413.69 Cr	382.12 Cr	401.32 Cr	390.98 Cr
Total Revenue	801.80 Cr	765.91 Cr	747.43 Cr	737.93 Cr
Operating Revenue	801.80 Cr	765.91 Cr	747.43 Cr	737.93 Cr
Tax Effect Of Unusual Items	0.09 Cr	-11.69 Cr	-0.48 Cr	-27.15 Cr
Tax Rate For Calcs	0.28	0.30	0.28	0.30
Normalized EBITDA	160.91 Cr	187.53 Cr	129.71 Cr	164.94 Cr
Total Unusual Items	0.32 Cr	-38.71 Cr	-1.72 Cr	-90.51 Cr
Total Unusual Items Excluding Goodwill	0.32 Cr	-38.71 Cr	-1.72 Cr	-90.51 Cr
Net Income From Continuing Operation Net Minority Interest	84.30 Cr	75.45 Cr	70.86 Cr	15.04 Cr
Reconciled Depreciation	29.42 Cr	26.38 Cr	18.67 Cr	17.33 Cr
Reconciled Cost Of Revenue	413.69 Cr	382.12 Cr	401.32 Cr	390.98 Cr

All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.

More on Bliss GVS Pharma Ltd

Overview Financials PE History Shareholding Quarterly Balance Sheet P&L Cash Flow Pharmaceuticals Stocks Screener

Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.